Phase 2 ASTX727 Trial: Cytidine Deaminase Inhibition in Accelerated/Blast-Phase MPNs

This Phase 2 trial by the National Cancer Institute compares ASTX727 alone versus ASTX727 plus iadademstat, an LSD1 inhibitor, in patients with accelerated or blast-phase Philadelphia chromosome-negative myeloproliferative neoplasms. The study evaluates if the combination enhances decitabine’s effects using structured treatment cycles and biomarker sampling.